 |
|
The Definition and Preoperative Prediction of Clinically Insignificant Prostate Cancer
James A. Dugan, MD;
David G. Bostwick, MD;
Robert P. Myers, MD;
Junqi Qian, MD;
Erik J. Bergstralh, MS;
Joseph E. Oesterling, MD
JAMA. 1996;275(4):288-294.
Abstract
| |
Objectives.
—To define clinically insignificant prostate cancer according to cancer volume, grade, cancer doubling time, and life expectancy; and to determine how many insignificant cancers are removed by radical prostatectomy.
Design and Patients.
—Clinically insignificant cancer was defined as a tumor that would give rise to no more than 20 cm3 of cancer within the prostate by the time of expected patient death (1990 life tables) and whose Gleason score was less than 4 in 40- to 49-year-olds, 5 in 50- to 59-year-olds, 6 in 60- to 69-year-olds, and 7 in 70- to 79-year-olds. Four definitions were formulated based on assumed cancer volume doubling times of 2, 3, 4, and 6 years. Using these four definitions, we reviewed 337 totally embedded prostates removed at Mayo Clinic between 1991 and 1993 for clinical stage T1c through T3 cancer to determine how many contained clinically insignificant cancer.
Main Outcome Measures.
—Clinically significant vs clinically insignificant prostate cancer.
Results.
—For cancer volume doubling time of 2, 3, 4, and 6 years, clinically in significant cancer was identified in one (0.3%), 13 (3.9%), 25 (7.4%), and 49 (14.5%) of 337 prostatectomy specimens, respectively.
Conclusions.
—Clinically insignificant prostate cancer can be defined by cancer volume, grade, cancer volume doubling time, and life expectancy of the patient. According to our definitions, most men treated with radical prostatectomy have clinically significant cancer.
(JAMA. 1996;275:288-294)
Author Affiliations
From the Departments of Urology (Drs Dugan, Myers, and Oesterling), Pathology (Drs Bostwick and Qian), and Biostatistics (Mr Bergstralh), Mayo Clinic and Mayo Foundation, Rochester, Minn. Dr Oesterling is now at the Michigan Prostate Institute, University of Michigan, Ann Arbor.
Footnotes
Reprint requests to the Michigan Prostate Institute, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109 (Dr Oesterling).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status
Mohan et al.
J Am Board Fam Med 2009;22:247-256.
ABSTRACT
| FULL TEXT
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?
Furusato et al.
J. Clin. Pathol. 2008;61:1038-1040.
ABSTRACT
| FULL TEXT
An Argument Against Routine Prostate Cancer Screening
Hoffman
Arch Intern Med 2003;163:663-665.
FULL TEXT
Rebuttal by Drs Oottamasathien and Crawford
Oottamasathien and Crawford
Arch Intern Med 2003;163:665-666.
FULL TEXT
Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era
Kakehi
Jpn J Clin Oncol 2003;33:1-5.
ABSTRACT
| FULL TEXT
Contemporary ultrasound guided biopsy in the diagnosis of prostate cancer
Clements
Imaging 2001;13:18-26.
FULL TEXT
Preoperative Prediction of Surgical Margin Status in Patients With Prostate Cancer Treated by Radical Prostatectomy
Cheng et al.
JCO 2000;18:2862-2868.
ABSTRACT
| FULL TEXT
Predicting Tumor Failure in Prostate Carcinoma after Definitive Radiation Therapy: Limitations of Models Based on Prostate-specific Antigen, Clinical Stage, and Gleason Score
Vollmer and Montana
Clin. Cancer Res. 1999;5:2476-2484.
ABSTRACT
| FULL TEXT
Early Detection of Prostate Cancer: Serendipity Strikes Again
Collins et al.
JAMA 1997;278:1516-1519.
ABSTRACT
Urology
Albertsen
JAMA 1997;277:1904-1905.
Defining Clinically Insignificant Prostate Cancer
Woolf
JAMA 1996;276:28-29.
ABSTRACT
FEW INSIGNIFICANT PROSTATE CANCERS REMOVED
JWatch General 1996;1996:4-4.
FULL TEXT
|
